Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial

Sheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, Meher Ben Abdelghani, Federica Morano, Amitesh Roy, Laetitia Dahan, Stefano Tamberi, Amandeep Singh Dhadda, Mark P Saunders, Nathalie Casanova, Rosine Guimbaud, Astrid Lievre, Joan Maurel, Marwan Fakih, Chuan Tian, Jill Harrison, Mark M Jones, Mark Cornfeld, Jean-Philippe Spano, Pauline Rochefort

Open source

DOI: 10.1016/s0140-6736(25)00631-2
Published: 2025-06
Container: The Lancet
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-00631-2,
  title = {Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial},
  author = {Sheela Rao and Emmanuelle Samalin-Scalzi and Ludovic Evesque and Meher Ben Abdelghani and Federica Morano and Amitesh Roy and Laetitia Dahan and Stefano Tamberi and Amandeep Singh Dhadda and Mark P Saunders and Nathalie Casanova and Rosine Guimbaud and Astrid Lievre and Joan Maurel and Marwan Fakih and Chuan Tian and Jill Harrison and Mark M Jones and Mark Cornfeld and Jean-Philippe Spano and Pauline Rochefort},
  year = {2025},
  journal = {The Lancet},
  doi = {10.1016/s0140-6736(25)00631-2},
  url = {https://doi.org/10.1016/s0140-6736(25)00631-2}
}

RIS

TY  - JOUR
TI  - Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial
AU  - Sheela Rao
AU  - Emmanuelle Samalin-Scalzi
AU  - Ludovic Evesque
AU  - Meher Ben Abdelghani
AU  - Federica Morano
AU  - Amitesh Roy
AU  - Laetitia Dahan
AU  - Stefano Tamberi
AU  - Amandeep Singh Dhadda
AU  - Mark P Saunders
AU  - Nathalie Casanova
AU  - Rosine Guimbaud
AU  - Astrid Lievre
AU  - Joan Maurel
AU  - Marwan Fakih
AU  - Chuan Tian
AU  - Jill Harrison
AU  - Mark M Jones
AU  - Mark Cornfeld
AU  - Jean-Philippe Spano
AU  - Pauline Rochefort
PY  - 2025
JO  - The Lancet
DO  - 10.1016/s0140-6736(25)00631-2
UR  - https://doi.org/10.1016/s0140-6736(25)00631-2
ER  -

APA

Rao, S., Samalin-Scalzi, E., Evesque, L., Abdelghani, M. B., Morano, F., Roy, A., Dahan, L., Tamberi, S., Dhadda, A. S., Saunders, M. P., Casanova, N., Guimbaud, R., Lievre, A., Maurel, J., Fakih, M., Tian, C., Harrison, J., Jones, M. M., Cornfeld, M., Spano, J., & Rochefort, P. (2025). Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(25)00631-2

Source records

crossref · retrieved 2026-09-27T01:14:26.695Z